<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23297823</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1873-5576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current cancer drug targets</Title>
          <ISOAbbreviation>Curr Cancer Drug Targets</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Diverse mechanisms of AKT pathway activation in human malignancy.</ArticleTitle>
        <Pagination>
          <StartPage>234</StartPage>
          <EndPage>244</EndPage>
          <MedlinePgn>234-44</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>AKT/PKB (Protein Kinase B) are central proteins mediating signals from receptor tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases are involved in a number of important cellular processes including cell proliferation and survival, cell size in response to nutrient availability, tumor invasion/metastasis, and angiogenesis.Various components of the AKT signaling pathway are encoded by tumor suppressor genes and oncogenes whose loss or activation, respectively, plays an important role in tumorigenesis. The growing body of evidence connecting deregulated AKT signaling with sporadic human cancers and inherited cancer predisposition syndromes is discussed. We also highlight new findings regarding the involvement of activating mutations of AKT1, AKT2, and AKT3 in somatic overgrowth disorders: Proteus syndrome, hypoglycemia with hypertrophy, and hemimegalencephaly, respectively. In addition, we review recent literature documenting the various ways the AKT signaling pathway is activated in human cancers and consequences for molecularly targeted therapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheung</LastName>
            <ForeName>Mitchell</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Testa</LastName>
            <ForeName>Joseph R</ForeName>
            <Initials>JR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA006927</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA077429</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA06927</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA77429</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Cancer Drug Targets</MedlineTA>
        <NlmUniqueID>101094211</NlmUniqueID>
        <ISSNLinking>1568-0096</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>CONFLICT OF INTEREST</b>. The authors confirm that this article content has no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2010</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23297823</ArticleId>
        <ArticleId IdType="mid">NIHMS457387</ArticleId>
        <ArticleId IdType="pmc">PMC3678724</ArticleId>
        <ArticleId IdType="doi">10.2174/1568009611313030002</ArticleId>
        <ArticleId IdType="pii">CCDT-EPUB-20130102-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16095999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003;546(1):108–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12829245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheon DJ, Orsulic S. Mouse Models of Cancer. Annu Rev Pathol. 2010;6:95–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20936938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res. 2006;12(18):5312–5328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17000664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10(5):508–515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19410195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tucker M, Goldstein A, Dean M, Knudson A. National Cancer Institute Workshop Report: the phakomatoses revisited. J Natl Cancer Inst. 2000;92(7):530–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10749907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009;11(10):687–694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19668082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol. 2004;15(2):177–182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15209377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23(16):2934–2949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15077155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3(11):973–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11715018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98(20):11598–11603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC58775</ArticleId>
            <ArticleId IdType="pubmed">11504915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S, Kim D, Dan HC, Chen H, Testa JR, Cheng JQ. Identification of an Akt interaction protein, PHF20/TZP, that transcriptionally regulates p53. J Biol Chem. 2012;287(14):11151–11163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3322870</ArticleId>
            <ArticleId IdType="pubmed">22334668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(20):10983–10985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC58668</ArticleId>
            <ArticleId IdType="pubmed">11572954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010;10(5):484–495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20384580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggero D, Sonenberg N. The Akt of translational control. Oncogene. 2005;24(50):7426–7434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005;24(50):7435–7442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3(3):179–192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12612653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell. 2004;5(6):519–523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15193254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 2008;8(1):19–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18288940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem. 2008;283(50):34495–34499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2596400</ArticleId>
            <ArticleId IdType="pubmed">18945681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bian CX, Shi Z, Meng Q, Jiang Y, Liu LZ, Jiang BH. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem Biophys Res Commun. 2010;398(3):395–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2928061</ArticleId>
            <ArticleId IdType="pubmed">20599538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu LZ, Zheng JZ, Wang XR, Jiang BH. Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. Cancer Res. 2008;68(19):8183–8188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18829578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci. 2008;65(24):3981–3999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18766298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10647931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90(12):1243–1250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12089061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT, Amin AR, Hamaguchi M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis. 2000;18(5):423–428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11467775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24(50):7443–7454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999;13(15):2091–2104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10593857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992;89(19):9267–9271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC50107</ArticleId>
            <ArticleId IdType="pubmed">1409633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64(4):280–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7657393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih Ie M, Wang TL. Amplicon profiles in ovarian serous carcinomas. Int J Cancer. 2007;120(12):2613–2617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17351921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, Schaefer B, Sehouli J, Dietel M, Lage H, Denkert C. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett. 2007;246(1–2):190–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16584837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y, Ma D. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 2008;261(1):108–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18171600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, Zhou J, Xu G, Meng L, Zhu T, Wang S, Ma D. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett. 2009;273(2):257–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18842333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003;63(1):196–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12517798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996;93(8):3636–3641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC39663</ArticleId>
            <ArticleId IdType="pubmed">8622988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miwa W, Yasuda J, Murakami Y, Yashima K, Sugano K, Sekine T, Kono A, Egawa S, Yamaguchi K, Hayashizaki Y, Sekiya T. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun. 1996;225(3):968–974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8780719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998;21(2):81–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9496907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Skele KL, Hoffman JP, Testa JR. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem. 2002;87(4):470–476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14735903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A, Furuya T, Tangoku A, Oka M, Sasaki K. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol. 2004;17(6):617–622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15133472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ichimura K, Vogazianou AP, Liu L, Pearson DM, Backlund LM, Plant K, Baird K, Langford CF, Gregory SG, Collins VP. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 2008;27(14):2097–2108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2650419</ArticleId>
            <ArticleId IdType="pubmed">17934521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2671642</ArticleId>
            <ArticleId IdType="pubmed">18772890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64(19):7002–7010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15466193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristiano BE, Chan JC, Hannan KM, Lundie NA, Marmy-Conus NJ, Campbell IG, Phillips WA, Robbie M, Hannan RD, Pearson RB. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res. 2006;66(24):11718–11725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17178867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448(7152):439–444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17611497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Grammastro MD, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A. AKT1(E17K) in human solid tumours. Oncogene. 2008;27(42):5648–5650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18504432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008;99(8):1265–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2570525</ArticleId>
            <ArticleId IdType="pubmed">18813315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, Sone K, Miyamoto Y, Hiraike H, Hiraike-Wada O, Nei T, Kawana K, Kuramoto H, Aburatani H, Yano T, Taketani Y. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009;101(1):145–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2713716</ArticleId>
            <ArticleId IdType="pubmed">19491896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen Y, Shalmon B, Korach J, Barshack I, Fridman E, Rechavi G. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol. 2010;116(1):88–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19853286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can cooperate with E17K. Oncogene. 2010;29(1):150–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19802009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. E17K substitution in AKT1 in prostate cancer. Br J Cancer. 2010;102(10):1491–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2869172</ArticleId>
            <ArticleId IdType="pubmed">20407443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2914105</ArticleId>
            <ArticleId IdType="pubmed">20602996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol. 2007;14(2):942–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17103252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9916799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2005;114(2):242–248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15543611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer. 2003;104(3):318–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12569555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106(12):4834–4839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2660768</ArticleId>
            <ArticleId IdType="pubmed">19261849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, Hou P. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer. 2012;12:50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3299648</ArticleId>
            <ArticleId IdType="pubmed">22292935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102(3):802–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC545580</ArticleId>
            <ArticleId IdType="pubmed">15647370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih Ie M. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597–1601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2671248</ArticleId>
            <ArticleId IdType="pubmed">19349352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR. Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670–3683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20453058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61(20):7426–7429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11606375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Aleman JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC, Kahn CR. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res. 2010;70(13):5305–5315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3204358</ArticleId>
            <ArticleId IdType="pubmed">20530665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2710138</ArticleId>
            <ArticleId IdType="pubmed">18767981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couto SS, Cao M, Duarte PC, Banach-Petrosky W, Wang S, Romanienko P, Wu H, Cardiff RD, Abate-Shen C, Cunha GR. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation. 2009;77(1):103–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828345</ArticleId>
            <ArticleId IdType="pubmed">19281769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 2002;277(42):39858–39866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12176997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol. 2010;14(3):412–420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20409745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Weiss HL, Rychahou P, Jackson LN, Evers BM, Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene. 2009;28(7):994–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2921630</ArticleId>
            <ArticleId IdType="pubmed">19079341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 2008;68(4):1012–1021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18281475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O’Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell. 2011;20(2):173–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3176728</ArticleId>
            <ArticleId IdType="pubmed">21840483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene. 2012;31(10):1264–1274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208076</ArticleId>
            <ArticleId IdType="pubmed">21804599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38(6):724–733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22082758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L, Jiang BH. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One. 2011;6(4):e19139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3081346</ArticleId>
            <ArticleId IdType="pubmed">21544242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou Y, Yang X, Wang F, Cui Z, Huang Y. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med. 2010;26(6):819–827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21042775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012;40(2):761–774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258133</ArticleId>
            <ArticleId IdType="pubmed">21917858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi ZM, Wang J, Yan Z, You YP, Li CY, Qian X, Yin Y, Zhao P, Wang YY, Wang XF, Li MN, Liu LZ, Liu N, Jiang BH. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1. PLoS One. 2012;7(3):e32709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3307714</ArticleId>
            <ArticleId IdType="pubmed">22442669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, Zhao YP, Liu WJ, Dong J, Chen WY, Zhang TP, Chen G, Shu H. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev Anticancer Ther. 2012;12(2):283–288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22316375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22(3):183–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12938083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet. 2007;81(4):756–767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2227925</ArticleId>
            <ArticleId IdType="pubmed">17847000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005;24(50):7475–7481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet. 2008;17(13):2006–2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2427143</ArticleId>
            <ArticleId IdType="pubmed">18397877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson JR. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans. 2009;37(Pt 1):259–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19143643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene. 2007;26(57):7825–7832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17599048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei C, Amos CI, Zhang N, Wang X, Rashid A, Walker CL, Behringer RR, Frazier ML. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res. 2008;14(4):1167–1171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18281551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei C, Amos CI, Zhang N, Zhu J, Wang X, Frazier ML. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. Cancer Lett. 2009;277(2):149–154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2966387</ArticleId>
            <ArticleId IdType="pubmed">19147279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, Vera DR, Shaw RJ. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A. 2009;106(27):11137–11142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2708689</ArticleId>
            <ArticleId IdType="pubmed">19541609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008;18(1):56–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18164202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van Brussel A, Voest EE, Giles RH. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20151405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010;61:329–343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2921612</ArticleId>
            <ArticleId IdType="pubmed">20059341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol. 2012;24(3):284–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3471654</ArticleId>
            <ArticleId IdType="pubmed">22343386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010;70(2):621–631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20068177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001;276(42):38349–38352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11533044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Science. 2001;292(5522):1728–1731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11387480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altomare DA, Lyons GE, Mitsuuchi Y, Cheng JQ, Testa JR. Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene. 1998;16(18):2407–2411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9620559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol. 2005;25(5):1869–1878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC549378</ArticleId>
            <ArticleId IdType="pubmed">15713641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O’Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med. 2011;365(7):611–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3170413</ArticleId>
            <ArticleId IdType="pubmed">21793738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen MM., Jr Proteus syndrome: an update. Am J Med Genet C Semin Med Genet. 2005;137C(1):38–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16010681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsh DJ, Trahair TN, Kirk EP. Mutant AKT1 in Proteus syndrome. N Engl J Med. 2011;365(22):2141–2142. author reply 2142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22129268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5(6):357–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18431376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen MM, Jr, Turner JT, Biesecker LG. Proteus syndrome: misdiagnosis with PTEN mutations. Am J Med Genet A. 2003;122A(4):323–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14518070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJ, Savage DB, Ramaswami U, De Lonlay P, O’Rahilly S, Barroso I, Semple RK. An activating mutation of AKT2 and human hypoglycemia. Science. 2011;334(6055):474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3204221</ArticleId>
            <ArticleId IdType="pubmed">21979934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BFD, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations. Neuron. 2012;74(1):41–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3460551</ArticleId>
            <ArticleId IdType="pubmed">22500628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tokuda S, Mahaffey CL, Monks B, Faulkner CR, Birnbaum MJ, Danzer SC, Frankel WN. A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice. Hum Mol Genet. 2011;20(5):988–999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3033189</ArticleId>
            <ArticleId IdType="pubmed">21159799</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
